Personalis Shares Rise 5% After VA Awards $13.5M Work Order.
ByAinvest
Friday, Aug 22, 2025 7:04 am ET1min read
PSNL--
The task order, which takes effect on September 30, 2025, subject to the receipt of samples and the fulfillment of services, is a significant milestone for the cancer test maker. Personalis, known for its NeXT Personal cancer test, provides genome sequencing services as part of the VA MVP contract. This new order is expected to contribute to the company's ongoing revenue growth.
To date, Personalis has received nearly $225 million in task orders under its contracts with the VA MVP, which accounted for 9% of its topline in 2024 and 13% in 2023, respectively [1]. The company has been focusing on expanding its presence in the VA MVP program, which has shown strong potential for growth.
The latest order comes as the company continues to refine its strategic focus and expand its service offerings. Personalis reported its Q2 2025 earnings call, outlining a $70 million to $80 million revenue target for the year, along with a 59% sequential clinical test growth and a revised biopharma outlook [1].
In the current financial climate, investors are closely monitoring Personalis' performance, particularly its ability to secure large-scale contracts and execute on its strategic goals. The latest VA MVP task order is a positive indicator of the company's market position and its potential for future growth.
References:
[1] https://seekingalpha.com/news/4488258-personalis-stock-gains-va-work-order
Personalis shares rise 5% in premarket trading after receiving a $13.5M task order from the Department of Veterans Affairs. The order is under a contract with the VA and marks a significant milestone for the cancer test maker. The company's stock has increased in value following the announcement.
Personalis Inc. (NASDAQ: PSNL) saw its stock rise by approximately 5% in premarket trading on Friday following the announcement that it had received a new task order worth up to $13.5 million from the Department of Veterans Affairs (VA). The order is part of the VA Million Veteran Program (MVP), a large-scale population sequencing initiative [1].The task order, which takes effect on September 30, 2025, subject to the receipt of samples and the fulfillment of services, is a significant milestone for the cancer test maker. Personalis, known for its NeXT Personal cancer test, provides genome sequencing services as part of the VA MVP contract. This new order is expected to contribute to the company's ongoing revenue growth.
To date, Personalis has received nearly $225 million in task orders under its contracts with the VA MVP, which accounted for 9% of its topline in 2024 and 13% in 2023, respectively [1]. The company has been focusing on expanding its presence in the VA MVP program, which has shown strong potential for growth.
The latest order comes as the company continues to refine its strategic focus and expand its service offerings. Personalis reported its Q2 2025 earnings call, outlining a $70 million to $80 million revenue target for the year, along with a 59% sequential clinical test growth and a revised biopharma outlook [1].
In the current financial climate, investors are closely monitoring Personalis' performance, particularly its ability to secure large-scale contracts and execute on its strategic goals. The latest VA MVP task order is a positive indicator of the company's market position and its potential for future growth.
References:
[1] https://seekingalpha.com/news/4488258-personalis-stock-gains-va-work-order

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet